Clostridium Difficile Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infection
Conditions: Clostridium Difficile Infection Interventions: Dietary Supplement: DBMF; Dietary Supplement: Placebo Sponsors: Vedic Lifesciences Pvt. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials

Safety Registry of a Fecal Microbiota Transplant Cohort
Conditions: Clostridium Difficile Infections Sponsors: Assistance Publique - H ôpitaux de Paris Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

C.Difficile Observational Study
Conditions: Clostridium Infections Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
Conditions: Antimicrobial Drug Resistance; Antibiotic Resistant Infection; Clostridium Difficile; Carbapenem-Resistant Enterobacteriaceae Infection; Extended Spectrum Beta-Lactamase Producing Bacteria Infection; Vancomycin Resistant Enterococci Infection; Carbapenem Resistant Bacterial Infection; Vancomycin-Resistant Enterococcal Infection Sponsors: The Methodist Hospital Research Institute; National Institute of Allergy and Infectious Diseases (NIAID); M.D. Anderson Cancer Center; Baylor College of Medicine; University of Houston; William Marsh Rice University; The University of Texas Health Science Center, Houston Recrui...
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials

A Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Conditions: Clostridium Difficile; Clostridium Difficile Infections; Clostridium Difficile Infection Recurrence; Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; CDI; C. Diff Infection; Recurrent Clostridium Difficile Infection; C.Difficile Diarrhea; Diarrhea Infectious Interventions: Biological: VE303; Biological: Placebo Sponsors: Vedanta Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Conditions: Clostridium Difficile; Clostridium Difficile Infections; Clostridium Difficile Infection Recurrence; Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; CDI; C. Diff Infection; Recurrent Clostridium Difficile Infection; C.Difficile Diarrhea; Diarrhea Infectious Interventions: Biological: VE303; Biological: Placebo Sponsors: Vedanta Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin which had eradication of C. difficile in 10 of 14 treated patients (71%). Ibezapolstat, but... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 17, 2024 Category: Pharmaceuticals Source Type: clinical trials

Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma
Conditions: Clostridium Difficile Infections Interventions: Other: Fecal microbiota transplant (Promicrobioma); Drug: Antibiotic Sponsors: Hospital Universitario Evangelico de Curitiba Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection
STATEN ISLAND, N.Y., Oct. 2, 2023. Acurx Pharmaceuticals, Inc. ( " Acurx " or the " Company " ), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 2, 2023 Category: Pharmaceuticals Source Type: clinical trials

Xylitol Use for Decolonization of C. Difficile in Patients With IBD
Conditions: Inflammatory Bowel Diseases; Clostridioides Difficile Infection Interventions: Drug: Xylitol; Drug: Sucralose Sponsor: Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 10, 2023 Category: Research Source Type: clinical trials